Preventing Long Term Complications
- 7 Downloads
Long term complications continue to be the major source of morbidity and mortality in patients with diabetes. Acarbose could potentially help to reduce diabetic complications if it improved glucose control, reduced lipid levels and hyperinsulinaemia. Acarbose has been shown to effectively reduce postprandial hyperglycaemia and haemoglobin A1c. This effect might be helpful in patients with insulin-dependent diabetes mellitus, as insulin injections do not provide complete control of rises in postprandial glucose levels, and in patients with non-insulin-dependent diabetes mellitus, because it simplifies the treatment programme. If improved control is shown to reduce complications, acarbose may be helpful. Although acarbose does not reduce hyperinsulinaemia, it reduces lipid levels and thus could reduce the risk of atherosclerosis.
KeywordsSulfonylurea Diabetic Complication Acarbose Blood Glucose Control Postprandial Hyperglycaemia
Unable to display preview. Download preview PDF.
- American Diabetes Association. Consensus statement: role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 12: 573–579, 1989Google Scholar
- Covet C, Ulmer M, Hamdaovi M, Bau HM, Debry G. Metabolic effects of acarbose in healthy men. European Journal of Clinical Nutrition 43: 187–196, 1989Google Scholar
- Innerfield R, Coniff RF, Shapiro JA, Collins S. A multicentre randomized comparative study of the efficacy of diet alone, acarbose (BAY g 5421) and diet, tolbutamide and diet, and acarbose (BAY g 5421) together with tolbutamide in the treatment of non-insulin-dependent (Type II) diabetes mellitus. Miles Medical Research Report Number 0992, 1989Google Scholar
- Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed between 1947 and 1973. Diabetes Care 1: 168–188, 252-263, 1978Google Scholar
- Schnack C, Prager RJF, Winkler J, Klauser RM, Schneider BG, et al. Effects of 8-week alpha-glucosidase inhibition on metabolic control. C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled Type II diabetic patients. Diabetes Care 12: 537–543, 1989Google Scholar
- Service FJ, Zimmerman BR, Rizza RA, Velosa JA, Frohnert PP, et al. Long-term metabolic control of IDDM who have received pancreatic allografts. Poster: Third International Congress on Pancreatic and Islet Transplantation, Lyon, June 1991Google Scholar